Skip to content

Trial Summary

A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012, With and Without Chemotherapy, in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Acronym:

CP-MGA271-05

ACTRN/NCT /ethics:

NCT04129320

Scientific title:

A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012, With and Without Chemotherapy, in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor / Cooperative group:

MacroGenics

Trial & Patient Characteristics

Cancer TypeMelanoma/Skin, Neck
Trial TypeTreatment
PhasePhase II, Phase III
Age Range18+ years
SexBoth
Tumour StreamMelanoma/Skin, Neck
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2019-10-01
Anticipated End Date2025-10-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusNot Yet Recruiting